BMS Touts Breyanzi's Outpatient Administration As EU Approval Beckons
Executive Summary
The US major won a positive opinion from the EU CHMP for Breyanzi with hopes the advantage of outpatient administration could help combat the lack of market impetus for CAR-T therapies.
You may also be interested in...
Mustang’s CAR-T MB-106 Shows Potential Competitiveness In CD20 Space
The company has maintained faith in autologous CAR-Ts, and its latest data show early signs of strong efficacy and favorable tolerability, possibly enabling outpatient use.
Bristol’s Growth Plan Faces First Test In 2022
Zeposia, Reblozyl, Breyanzi and Abecma turned BMS’s new product portfolio into a blockbuster revenue stream last year to help fill the $3.5bn gap created by Revlimid and Abraxane generics.
BMS’ Cell Therapy For Lymphoma On Track For EU-Wide Approval
Several new drugs are now on track for an EU marketing authorization after getting the EMA’s thumbs up this week.